Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

CNTX Context Therapeutics

Watchlist
0.700
-0.027-3.71%
Close  01/27 16:00 ET
0.691
-0.009-1.29%
Post Mkt Price 01/27 18:53 ET
High
0.730
Open
0.718
Turnover
76.95K
Low
0.691
Pre Close
0.727
Volume
108.81K
Market Cap
11.18M
P/E(TTM)
Loss
52wk High
2.790
Shares
15.97M
P/E(Static)
Loss
52wk Low
0.600
Float Cap
6.22M
Bid/Ask %
-87.50%
Historical High
10.870
Shs Float
8.89M
Volume Ratio
0.74
Historical Low
0.600
Dividend TTM
--
Div Yield TTM
--
P/B
0.29
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.22%
Amplitude
5.35%
Avg Price
0.707
Lot Size
1
Float Cap
6.22M
Bid/Ask %
-87.50%
Historical High
10.870
Shs Float
8.89M
Volume Ratio
0.74
Historical Low
0.600
Dividend TTM
--
P/B
0.29
Dividend LFY
--
Turnover Ratio
1.22%
Amplitude
5.35%
Avg Price
0.707
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
CEO: Mr. Martin Lehr
Market: NASDAQ
Listing Date: 10/20/2021
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist